CymaBay announces positive interim results from its ongoing low-dose phase 2 study
CymaBay Therapeutics announced positive interim results from its ongoing low-dose Phase 2 study of seladelpar in patients with primary biliary cholangitis. There were no serious adverse events and no safety transaminase signal was observed at either dose. July 17, 2017